iSpecimen Reschedules Full Year 2023 Earnings Release and Conference Call

The Company will now report results after the market closes on March 13, 2024 and reschedules conference call to Thursday, March 14, 2024 at 8:30am EasternLEXINGTON, Mass., March 12, 2024 (GLOBE NEWSWIRE) — iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today announced that it will report its financial results for the full year ended December 31, 2023 after the market closes on Wednesday, March 13, 2024. The Company had previously announced it would report its financial results before the market opens on March 13, 2024, with the conference call taking place at 8:30 a.m. Eastern Time on March 13, 2024. The Company will now host a conference call and audio webcast on Thursday, March 14, 2024 at 8:30 a.m. Eastern Time featuring remarks by Tracy Curley, CEO. Event:iSpecimen Year End 2023 Results Conference CallDate:Thursday, March 14, 2024Time:8:30 a.m. Eastern TimeDial in:1-888-886-7786 (U.S. Toll Free) or 1-416-764-8658 (International)Webcast:https://viavid.webcasts.com/starthere.jsp?ei=1655659&tp_key=8493197d5b   For interested individuals unable to join the conference call, a replay will be available through March 28, 2024, at +1-844-512-2921 (U.S. Toll Free) or +1-412-317-6671 (International). Participants must use the following code to access the replay of the call: 37478374. An archived version of the webcast will also be available on iSpecimen’s Investor Relations site: https://investors.ispecimen.com/presentations/. About iSpecimen iSpecimen (Nasdaq: ISPC) offers an online marketplace for human biospecimens, connecting scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers and other healthcare organizations. For more information, please visit www.ispecimen.com. Forward Looking Statements This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are characterized by future or conditional verbs such as “may,” “will,” “expect,” “intend,” “anticipate,” “believe,” “estimate” and “continue” or similar words. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to the risks factors contained in the Company’s filings with the Securities and Exchange Commission, which are available for review at www.sec.gov. Forward-looking statements speak only as of the date they are made. New risks and uncertainties arise over time, and it is not possible for the Company to predict those events or how they may affect the Company. If a change to the events and circumstances reflected in the Company’s forward-looking statements occurs, the Company’s business, financial condition and operating results may vary materially from those expressed in the Company’s forward-looking statements. Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise. For further information, please contact: Investor ContactKCSA Strategic CommunicationsPhilip [email protected] Media ContactsKCSA Strategic CommunicationsRaquel Cona / Michaela [email protected]